119 related articles for article (PubMed ID: 26603719)
1. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
Giraldo P; Pérez-López J; Núñez R; de la Puebla RF; Luño E; Saura-Grau S; Bureo JC; Plaza S; de la Serna J
Blood Cells Mol Dis; 2016 Jan; 56(1):23-30. PubMed ID: 26603719
[TBL] [Abstract][Full Text] [Related]
2. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
3. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
4. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
Weinreb N; Taylor J; Cox T; Yee J; vom Dahl S
Am J Hematol; 2008 Dec; 83(12):890-5. PubMed ID: 18819093
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina.
Oliveri B; González D; Quiroga F; Silva C; Rozenfeld P
Calcif Tissue Int; 2019 Jun; 104(6):650-657. PubMed ID: 30790003
[TBL] [Abstract][Full Text] [Related]
7. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
[TBL] [Abstract][Full Text] [Related]
8. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.
Herrera S; Pérez-López J; Moltó-Abad M; Güerri-Fernández R; Cabezudo E; Novelli S; Esteve J; Hernández A; Roig I; Solanich X; Prieto-Alhambra D; Nogués X; Díez-Pérez A
J Bone Miner Res; 2017 Jul; 32(7):1575-1581. PubMed ID: 28263001
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics of type I Gaucher's disease in Spain. Preliminary results of national survey. Spanish Group on Gaucher's Disease].
Giraldo P; Pérez-Calvo JI; Giralt M; Pocovi M
Med Clin (Barc); 1997 Nov; 109(16):619-22. PubMed ID: 9463135
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status.
Jaramillo D; Bedoya MA; Wang DJ; Pena AH; Delgado J; Jaimes C; Ho-Fung V; Kaplan P
AJR Am J Roentgenol; 2015 Jun; 204(6):1296-302. PubMed ID: 26001241
[TBL] [Abstract][Full Text] [Related]
13. The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises.
Andrade-Campos M; Valero E; Roca M; Giraldo P;
Blood Cells Mol Dis; 2018 Feb; 68():126-134. PubMed ID: 27836527
[TBL] [Abstract][Full Text] [Related]
14. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
15. [Quality study of diagnostic and follow-up procedures of bone involvement in type 1 Gaucher"s disease in Spain].
Pérez Calvo JI; Giraldo Castellano P; Rubio-Félix D; Giralt Reichs M; Pocoví Mieras M
An Med Interna; 2003 Dec; 20(12):607-11. PubMed ID: 14697079
[TBL] [Abstract][Full Text] [Related]
16. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
17. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
18. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
[TBL] [Abstract][Full Text] [Related]
19. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1.
Lorenz F; Pawłowicz E; Klimkowska M; Beshara S; Bulanda Brustad A; Skotnicki AB; Wahlin A; Machaczka M
Blood Cells Mol Dis; 2018 Feb; 68():35-42. PubMed ID: 27816428
[TBL] [Abstract][Full Text] [Related]
20. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone.
Mikosch P
Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):665-81. PubMed ID: 22142746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
